Latest Conference Articles

Peter Lio, MD, discusses why precision medicine has advanced further in psoriasis than atopic dermatitis, and what oncology can teach dermatology.

Peter Lio, MD, on Skin Angels, a dermatology-focused angel-investing group that has evaluated over 300 companies and funded more than 30.

Steven Daveluy, MD, speaks on why dermatologists belong on social media, avoiding burnout in practice, and what excites him in HS treatment.

The investigational therapy did not achieve statistical significance in KCCQ-TSS or in 6MWD, but saw substantial changes in exploratory secondary endpoints.

H-ISDN missed its primary endpoint in H-HeFT, but a pooled meta-analysis found significant reductions in all-cause and cardiovascular death in HFrEF.

Christie Ballantyne, MD, unpacks SHASTA-3/4 results on plozasiran for severe hypertriglyceridemia, from triglyceride reduction to pancreatitis prevention.

The China Rural Hypertension Control Program found a non-physician-led intensive blood pressure intervention reduced dementia risk by 15% over 7 years.

A dermatologist-turned-entrepreneur on why clinicians belong in dermatology's investment decisions, and what excites her about the field's direction.

Lisa Swanson, MD, on embracing failure in medicine and the oral JAK inhibitors advancing for hidradenitis suppurativa and alopecia areata.

Ashkan Shoamanesh, MD, discusses individualizing stroke prevention after ENRICH-AF, from LAAO to factor XI inhibitors to the ASPIRE trial.

SHASTA-3 and SHASTA-4 found plozasiran cut triglycerides by roughly 80% and acute pancreatitis events by 78% in severe hypertriglyceridemia.

Luke Laffin, MD, discusses 1-year data showing CTX310 produced durable reductions in ANGPTL3, LDL cholesterol, and triglycerides.

CMR GUIDE found ICD implantation did not significantly reduce sudden cardiac death or dangerous arrhythmia versus a loop recorder in LVEF 36-50%.

Ronald Witteles, MD, explains why CARDIO-TTRansform's miss doesn't undermine TTR silencers as a class for treating ATTR-CM.

Phase 2b LUMINARA results showed the oral relaxin agonist AZD5462 improved echocardiographic measures of cardiac function in patients with chronic heart failure.

The Met-HeFT trial and a companion meta-analysis found metformin did not significantly improve cardiovascular outcomes in patients with HFrEF.

Lisa Swanson, MD, on treating professional failure as a source of direction and resilience in her LEADderm 2026 talk.

Adam Friedman, MD, traces dermatology's yes-first culture to residency competition, previewing an unrehearsed LEADderm 2026 negotiation exercise.

A roundup of the top cardiology news out of ESC Congress2026 on day 2, spanning primary prevention, novel therapies, and antibiotic stewardship.

Adam Friedman, MD, discusses saying no strategically as a career skill in a LEADderm 2026 table talk on managing opportunities.

New MILOS data show bempedoic acid-based therapy translated to meaningful reductions in predicted 10-year cardiovascular risk.

Anjali Vaidya, MD, breaks down sotatercept's distinct effects on RV afterload, structure, and function in pulmonary arterial hypertension.

The REACT study found silent atherosclerosis in 57.1% of adults without known cardiovascular disease, a burden largely missed by the SCORE2 risk tool.

Steven Nissen, MD, shares key takeaways on AAV8, CTX310, and Kylo-11 gene and molecular therapies presented at ESC Congress 2026.

A longitudinal survey found PSVT disrupts patients' daily activities, sleep, and emotions between episodes.

Despite failing to display a clinically significant reduction in all-cause death or hospitalization for cardiovascular events, the trial did highlight evolocumab’s LDL-C-lowering capacity.

CTX310, a CRISPR-Cas9 therapy targeting ANGPTL3, sustained deep LDL and triglyceride reductions at 1 year after a single infusion, per ESC 2026 data.

Erin Michos, MD, MHS, explains why hypertension risk rises earlier in women and how aldosterone and menopause drive that risk.